Des Moines venture capital firm Next Level Ventures announced it has raised more than $15 million so far for Next Level Ventures Fund 3 and completed its first investment from the fund. The fund is NLV’s third Iowa-focused investment fund and fifth overall. The fund’s first investment is in Ames-based Genvax Technologies, which is developing mRNA + nanoparticle animal vaccines. “Genvax is excited to welcome Next Level Ventures to our seed round,” said Joel Harris, CEO and co-founder of Genvax. “Their support reinforces why Iowa is the ideal place to build and scale innovative animal biotech companies. With its deep agricultural roots, world-class research institutions, and strong investor network, Iowa provides the perfect ecosystem for advancing next-generation animal health solutions.” The fund remains open to accredited investors, the release said. To learn more about the launch of the fund, read this innovationIOWA story.
